190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
2016 ◽
Vol 11
(4)
◽
pp. S139
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. e18062-e18062
2019 ◽
Vol 117
◽
pp. 107-115
◽
Keyword(s):